Organs on ChipsMarketwas valued at USD 28.1 Million in 2021 and is projected to reach USD 125.7 Million by 2028, growing at a Compound Annual Growth Rate (CAGR) of 28.1% from 2022 to 2028. Organs on Chips (OOC) is a microfluidic cell culture tool, manufactured using microchip production techniques that consist of continuous fragrant containers housed by living cells designed to mimic tissue body and organ level. This chip creates a small blood vessel and airway in organs such as the lungs, intestines, liver, heart, and others. Such machines produce high levels of tissue and organs, which is not possible using standard 2D and 3D systems. Organs on Chips offers many different programs such as disease modeling, patient classification, and phenotypic testing.
Organs on Chipss are considered more relevant and accurate than animal or cultural models of cells in drug detection and development. Organs on Chips’s allows the flexibility of personalizing medicine to specifically target the need of patient. These personalized medical models help predict specific patient toxicity and success rate. In the future, by focusing on early diagnosis with the help of personal medication, patients will be paired with the most appropriate treatment that will work for them. However, the cost of these chips and the redesign steps to match mass production are high. The high cost of production hinders Organs on Chips Market growth as an expensive redesign process can be a burden on the smaller companies involved. In addition, the conceptual design of bioreactors, cell culture medium mixing pumps, cell storage, mechanical regeneration, and the use of cellular analysis techniques are all complex and require additional costs. The costs incurred in product promotions may also reflect the price of chip, making it unaffordable for pharmaceutical companies. Creating an Organs on Chips is also not an easy process and the challenges that need to be overcome in this process include reproducing the complex structure of the tissue and human organs in the device in a small way, and connecting and organizing them in the right way. In addition, many companies in the pharmaceutical industry will have to switch from polydimethylsiloxane (PDMS) prototyping and sub-series to large-scale production of other materials (glass, polymer injection molding) that will increase costs and potentially delay growth.
Based on the application, the organ-on-chips market is divided by physiological model development, drug discovery, disease modeling, food safety, molecular biology and toxicology research. Based on organ type the market is segmented as liver, heart, lungs, intestine, kidney, skin, and other organs. Based on end user the market is segmented as pharmaceutical and biotechnology companies, academic and research institutes and other commercial industries. On the basis of regional analysis, the global organ-on-chips market is categorized as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.North America has been a dominating region whileAsia Pacificshows the fastest rate of growth in terms of share in total market size.
Major players in this Global Organs on Chips Market includeAxoSim Inc., BiomimX SRL, Elveflow, Emulate Inc., Hurel Corporation, InSphero AG, MIMETAS BV, Nortis Inc., Tara Biosystems Inc., and TissUse GmbH